LLY

1,011.3

-0.72%↓

JNJ

243.41

-1.2%↓

ABBV

226

+0.68%↑

NVS

163.25

-0.09%↓

MRK

121.68

-0.49%↓

LLY

1,011.3

-0.72%↓

JNJ

243.41

-1.2%↓

ABBV

226

+0.68%↑

NVS

163.25

-0.09%↓

MRK

121.68

-0.49%↓

LLY

1,011.3

-0.72%↓

JNJ

243.41

-1.2%↓

ABBV

226

+0.68%↑

NVS

163.25

-0.09%↓

MRK

121.68

-0.49%↓

LLY

1,011.3

-0.72%↓

JNJ

243.41

-1.2%↓

ABBV

226

+0.68%↑

NVS

163.25

-0.09%↓

MRK

121.68

-0.49%↓

LLY

1,011.3

-0.72%↓

JNJ

243.41

-1.2%↓

ABBV

226

+0.68%↑

NVS

163.25

-0.09%↓

MRK

121.68

-0.49%↓

Search

CareDx Inc

Open

SectorGezondheidszorg

19.8

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

19.68

Max

19.9

Belangrijke statistieken

By Trading Economics

Inkomsten

10M

1.7M

Verkoop

13M

100M

K/W

Sectorgemiddelde

15.336

110.024

Winstmarge

1.674

Werknemers

644

EBITDA

11M

6.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-9.41% downside

Dividenden

By Dow Jones

Volgende Winsten

24 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

259M

1B

Vorige openingsprijs

19.8

Vorige sluitingsprijs

19.8

Nieuwssentiment

By Acuity

16%

84%

30 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 feb 2026, 23:47 UTC

Marktinformatie

Global Equities Roundup: Market Talk

19 feb 2026, 23:47 UTC

Marktinformatie

Nikkei May Decline Amid Caution Over Potential U.S. Strike on Iran -- Market Talk

19 feb 2026, 23:39 UTC

Acquisities, Fusies, Overnames

Swiss Re Corporate Solutions to Buy QBE Insurance's Global Trade Credit and Surety Business >SREN.EB

19 feb 2026, 23:38 UTC

Winsten

Samsung Fire & Marine Insurance 2025 Net KRW2.020T Vs. Net KRW2.077T >000810.SE

19 feb 2026, 23:38 UTC

Winsten

Samsung Fire & Marine Insurance 2025 Oper Pft KRW2.659T Vs. Pft KRW2.650T >000810.SE

19 feb 2026, 23:38 UTC

Winsten

Samsung Fire & Marine Insurance 2025 Rev KRW24.779T Vs. KRW22.657T >000810.SE

19 feb 2026, 23:37 UTC

Marktinformatie

Gold Edges Lower on Possible Position Adjustment -- Market Talk

19 feb 2026, 23:34 UTC

Winsten

Samsung Fire & Marine Insurance 4Q Net Profit Missed FactSet-Compiled Consensus

19 feb 2026, 23:34 UTC

Winsten

Samsung Fire & Marine Insurance 4Q Net KRW234.38B Vs. Net KRW207.88B >000810.SE

19 feb 2026, 23:33 UTC

Winsten

Samsung Fire & Marine Insurance 4Q Oper Pft KRW391.26B Vs. Pft KRW252.81B >000810.SE

19 feb 2026, 23:33 UTC

Winsten

Samsung Fire & Marine Insurance 4Q Rev KRW6.083T Vs. KRW6.297T >000810.SE

19 feb 2026, 22:13 UTC

Marktinformatie

Goodman's Lack of Earnings Upgrade 'Largely Timing Related' -- Market Talk

19 feb 2026, 22:08 UTC

Winsten

Fairfax Financial 4Q Rev $8.11B >FFH.T

19 feb 2026, 22:07 UTC

Winsten

Eldorado Gold 4Q EPS $1.19 >ELD.T

19 feb 2026, 22:06 UTC

Winsten

Centerra Gold: 2026 Consolidated Gold Production Expected 250,000 to 280,000 Ounces, Copper Production Expected 50M to 60M Pounds >CG.T

19 feb 2026, 22:05 UTC

Winsten

Eldorado Gold 4Q Adj EPS 63c >ELD.T

19 feb 2026, 22:05 UTC

Winsten

Eldorado Gold 4Q Rev $577.2M >ELD.T

19 feb 2026, 22:04 UTC

Winsten

Eldorado Gold 4Q Gold Sales 126,923 Ounces >ELD.T

19 feb 2026, 22:04 UTC

Winsten

Eldorado Gold 4Q Gold Production 123,416 Ounces >ELD.T

19 feb 2026, 21:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

19 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

19 feb 2026, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

19 feb 2026, 21:43 UTC

Winsten

St Barbara 1H Underlying Profit A$1.3 Million Vs A$48.1 Million Loss Year Earlier

19 feb 2026, 21:42 UTC

Acquisities, Fusies, Overnames

Palo Alto Networks Announces Offer to Purchase Relating to CyberArk Software Ltd.'s 0.00% Convertible Senior Notes Due 2030

19 feb 2026, 21:42 UTC

Winsten

St Barbara 1H Revenue A$128.8 Million, Up 32% On-Year

19 feb 2026, 21:41 UTC

Winsten

Correct: St Barbara 1H Net Loss A$249,000

19 feb 2026, 21:40 UTC

Winsten

St Barbara 1H Net Loss A$249 Million

19 feb 2026, 21:39 UTC

Winsten

Perseus Mining Reaffirms FY26 Production, AISC Guidance

19 feb 2026, 21:37 UTC

Winsten

These Stocks Are Today's Movers: Walmart, Occidental, Klarna, Wayfair, Deere, Omnicom, EPAM, and More -- Barrons.com

19 feb 2026, 21:37 UTC

Winsten

Century Aluminum Expects 1Q Adj EBITDA $215 M to $235 M >CENX

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

-9.41% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 18 USD  -9.41%

Hoogste 18 USD

Laagste 18 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

3 ratings

0

Buy

3

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

30 / 351 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat